Robust Put Option Volume Highlights Bearish Hedging
On 14 July 2026, Divis Laboratories (NSE: DIVISLAB) emerged as the most active stock in put options trading, with 5,331 contracts changing hands at the 7,000 strike price for the expiry dated 28 July 2026. This surge in put option activity generated a turnover of approximately ₹66.0 crores, reflecting substantial investor interest in downside protection or bearish positioning.
The open interest at this strike stands at 1,164 contracts, indicating that a sizeable number of traders are maintaining bearish bets or hedges against potential price declines. Given the underlying stock price of ₹7,066 at the time, the 7,000 strike puts are positioned slightly out-of-the-money, suggesting cautious sentiment among option traders despite the stock’s recent gains.
Price Action and Technical Context
Divis Laboratories has been on a steady upward trajectory, hitting a new 52-week high of ₹7,110 on the day of the option activity. The stock outperformed its Pharmaceuticals & Biotechnology sector by 1.02% and the broader Sensex by a notable margin, with a 1-day return of 1.87% compared to the sector’s 0.90% gain and Sensex’s 0.44% decline.
Moreover, the stock has recorded four consecutive days of gains, accumulating a 4.61% return over this period. It is trading comfortably above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — underscoring a strong technical uptrend.
However, a decline in delivery volume by 33.73% compared to the 5-day average suggests waning investor participation in the recent rally, which may be prompting some market participants to seek downside protection through put options.
Market Capitalisation and Quality Assessment
Divis Laboratories commands a large market capitalisation of ₹1,84,660 crores, positioning it as a heavyweight in the Pharmaceuticals & Biotechnology sector. The company’s Mojo Score currently stands at 64.0, with a Mojo Grade of Hold, reflecting a recent downgrade from Buy on 29 June 2026. This adjustment signals a more cautious outlook from analysts, possibly influenced by valuation concerns or sector headwinds.
Expiry Patterns and Investor Behaviour
The expiry date of 28 July 2026 is attracting heightened option activity, a common phenomenon as traders adjust positions ahead of contract settlements. The concentration of put options at the 7,000 strike price, close to the current market price, indicates that investors are hedging against a potential pullback or volatility in the near term.
Such positioning can also be interpreted as a tactical move by institutional investors to protect profits after the recent rally, especially given the stock’s stretched technical indicators and reduced delivery volumes.
Implications for Investors and Traders
For investors, the heavy put option activity at near-the-money strikes suggests a cautious stance prevailing in the market despite the stock’s strong fundamentals and recent price strength. While the technicals remain bullish, the increased demand for downside protection may reflect concerns over short-term volatility or sector-specific risks.
Traders should monitor the open interest and volume trends in both put and call options as the expiry approaches to gauge shifts in market sentiment. A sustained increase in put open interest coupled with price weakness could signal a correction, whereas a decline in put activity might reaffirm the bullish momentum.
Sector and Broader Market Context
The Pharmaceuticals & Biotechnology sector has shown resilience, but selective profit-taking and cautious positioning in large-cap stocks like Divis Laboratories highlight the nuanced investor approach amid global macroeconomic uncertainties and regulatory developments impacting the industry.
Compared to the broader market, Divis Laboratories’ outperformance is notable, yet the downgrade in Mojo Grade and the surge in put options underline the importance of balanced risk management strategies for portfolio managers and retail investors alike.
Conclusion: Balancing Optimism with Prudence
Divis Laboratories’ recent price highs and sector outperformance are tempered by significant put option activity, signalling that market participants are hedging against potential downside risks. The stock’s technical strength remains intact, but the evolving options landscape suggests investors should remain vigilant and consider protective strategies in their holdings.
As the 28 July expiry approaches, the interplay between price action and options positioning will provide critical insights into the stock’s near-term trajectory, making Divis Laboratories a key focus for traders and investors navigating the Pharmaceuticals & Biotechnology sector.
